Immunotherapy

Koen van Besien, MD, PhD, has been appointed chief of the division of hematology at University Hospitals Seidman Cancer Center.

Interleukin-6 blockade appeared effective against immune-related adverse events among a small cohort of patients treated with immune checkpoint inhibitors for melanoma, according to study results published in Cancer Cell.

CHICAGO — For patients with advanced non-small cell lung cancer who showed an inadequate response to front-line immunotherapy checkpoint inhibitors and chemotherapy, the addition of CAN-2409 was well-tolerated.

Various sociodemographic and socioeconomic factors, including race/ethnicity and insurance status, correlated with receipt of immunotherapy among patients with melanoma and kidney and lung cancers.

In this video, Melina Marmarelis, MD, highlights findings from a Lung-MAP nonmatched substudy presented at ASCO Annual Meeting.

Obesity appeared associated with improved immunotherapy outcomes among patients with certain cancer types, according to a cohort study published in JAMA Network Open.

CHICAGO — Acetaminophen suppressed antitumor immunity in a cohort of patients with cancer, according to study results presented during ASCO Annual Meeting.

CHICAGO — Adjuvant pembrolizumab significantly improved distant metastasis-free survival among patients with resected stage IIB or IIC melanoma, according to results of the phase 3 KEYNOTE-716 presented at ASCO Annual Meeting.

CHICAGO — Chemoimmunotherapy and immunotherapy alone conferred comparable benefit as first-line therapy for most patients with advanced non-small cell lung cancer and high PD-L1 expression, results presented at ASCO Annual Meeting showed.

Women demonstrated a 34% increased risk for severe adverse events from any cancer treatment compared with men, according to a study published in Journal of Clinical Oncology.